CY1112284T1 - Ενωσεις τετραϋδροκυκλοπεντα[β] ινδολιου ως ρυθμιστες υποδοχεων ανδρογονων - Google Patents
Ενωσεις τετραϋδροκυκλοπεντα[β] ινδολιου ως ρυθμιστες υποδοχεων ανδρογονωνInfo
- Publication number
- CY1112284T1 CY1112284T1 CY20121100148T CY121100148T CY1112284T1 CY 1112284 T1 CY1112284 T1 CY 1112284T1 CY 20121100148 T CY20121100148 T CY 20121100148T CY 121100148 T CY121100148 T CY 121100148T CY 1112284 T1 CY1112284 T1 CY 1112284T1
- Authority
- CY
- Cyprus
- Prior art keywords
- tetrahyrocyclipse
- indoli
- regulators
- units
- compound
- Prior art date
Links
- 102000001307 androgen receptors Human genes 0.000 title 1
- 108010080146 androgen receptors Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 1
- 206010049088 Osteopenia Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86648406P | 2006-11-20 | 2006-11-20 | |
| EP07844898A EP2094658B1 (en) | 2006-11-20 | 2007-11-06 | Tetrahydrocyclopenta[b]indole compounds as androgen receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1112284T1 true CY1112284T1 (el) | 2015-12-09 |
Family
ID=39415431
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121100148T CY1112284T1 (el) | 2006-11-20 | 2012-02-14 | Ενωσεις τετραϋδροκυκλοπεντα[β] ινδολιου ως ρυθμιστες υποδοχεων ανδρογονων |
Country Status (36)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8268872B2 (en) | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
| BRPI0907844B8 (pt) | 2008-02-22 | 2021-05-25 | Radius Health Inc | compostos e método para modular um receptor de andrógeno, processos de preparação e composição farmacêutica dos mesmos e seus usos |
| ES2396612T3 (es) * | 2008-05-16 | 2013-02-22 | Eli Lilly & Company | Tetrahidrociclopenta[b]indoles como moduladores del receptor de andrógenos |
| AR078862A1 (es) | 2009-11-13 | 2011-12-07 | Lilly Co Eli | Ester isopropilico del acido ((s)-7-ciano-4-((2r,3s)-3-hidroxitetrahidrofuran-2-ilmetil)-1,2,3,4-tetrahidro-ciclopenta(b)indol-2-il)carbamico, composiciones farmaceuticas que lo comprenden y su uso en terapia |
| JP5964756B2 (ja) | 2010-02-04 | 2016-08-03 | ラジウス ヘルス，インコーポレイテッド | 選択的アンドロゲン受容体モジュレーター |
| DK2568806T3 (en) | 2010-05-12 | 2016-08-15 | Radius Health Inc | therapy Programs |
| US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
| EP2621901B1 (en) | 2010-09-28 | 2015-07-29 | Radius Health, Inc | Selective androgen receptor modulators |
| BR112013028895A2 (pt) | 2011-05-10 | 2016-08-09 | Bayer Ip Gmbh | (tio)carbonilamidinas bicíclicas |
| CN103265479B (zh) * | 2013-06-14 | 2017-12-08 | 南开大学 | 一种6‑氯甲基烟酸叔丁酯的合成方法 |
| CA2943611A1 (en) | 2014-03-28 | 2015-10-01 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| TWI677489B (zh) | 2014-06-20 | 2019-11-21 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| JOP20180072A1 (ar) * | 2014-09-11 | 2019-01-30 | Lilly Co Eli | علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين |
| SG11201811225RA (en) | 2016-06-22 | 2019-01-30 | Radius Health Inc | Ar+ breast cancer treatment methods |
| US20180185347A1 (en) | 2016-11-16 | 2018-07-05 | Transition Therapeutics (Ireland 2) Limited | Tetrahydrocyclopenta[b]indole compounds and phosphodiesterase inhibitors for the treatment of the signs and symptoms of bhp |
| KR102881465B1 (ko) | 2017-01-05 | 2025-11-04 | 래디어스 파마슈티컬스, 인코포레이티드 | Rad1901-2hcl의 다형 형태 |
| AU2019297421B2 (en) | 2018-07-04 | 2024-08-29 | Radius Pharmaceuticals, Inc. | Polymorphic forms of RAD 1901-2HCL |
| CA3128510A1 (en) | 2019-02-12 | 2020-08-20 | Radius Pharmaceuticals, Inc. | Processes and compounds |
| JP2023511612A (ja) * | 2020-01-27 | 2023-03-20 | エイルゲン ファーマ リミテッド | 腎臓疾患の治療のためのテトラヒドロシクロペンタ［ｂ］インドール化合物 |
| US11986461B1 (en) * | 2023-08-24 | 2024-05-21 | King Faisal University | 3-(1-(3-(dimethylamino)propyl)-4,5-diphenyl-1H-imidazol-2-yl)pyridin-2-ol as an antitumor and antimicrobial compound |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4988820A (en) | 1986-02-21 | 1991-01-29 | Bayer Aktiengesellschaft | Cycloalkano(1,2-B) indole-sulponamides |
| GB8924392D0 (en) | 1989-10-30 | 1989-12-20 | Bayer Ag | Substituted cycloalkano/b/dihydroindole-and-indolesulphonamides |
| GB9008108D0 (en) | 1990-04-10 | 1990-06-06 | Bayer Ag | Cycloalkano(b)dihydroindoles and-indolesulphonamides substituted by heterocycles |
| DE4027278A1 (de) | 1990-08-29 | 1992-03-05 | Bayer Ag | Heterocyclisch substituierte indolsulfonamide |
| DE4131346A1 (de) | 1991-09-20 | 1993-03-25 | Bayer Ag | Indolsulfonamid substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln |
| WO2001027086A1 (en) * | 1999-10-14 | 2001-04-19 | Kaken Pharmaceutical Co., Ltd. | Tetrahydroquinoline derivatives |
| US7160909B2 (en) | 2001-08-09 | 2007-01-09 | Eli Lilly And Company | Cyclopenta[b]indole derivatives as sPLA2 inhibitors |
| DE10164564B4 (de) | 2001-12-14 | 2007-05-16 | Zentaris Gmbh | Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR) |
| WO2003097598A1 (en) | 2002-05-16 | 2003-11-27 | Shionogi & Co., Ltd. | Compound exhibiting pgd 2 receptor antagonism |
| US20060074124A1 (en) | 2003-09-12 | 2006-04-06 | Andrew Napper | Methods of treating a disorder |
| US20050245540A1 (en) * | 2003-12-09 | 2005-11-03 | Fujisawa Pharmaceutical Co., Ltd. | New methods |
| US7019022B2 (en) | 2003-12-15 | 2006-03-28 | Merck Frosst Canada & Co. | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives |
| ES2414604T3 (es) * | 2004-03-03 | 2013-07-22 | Eli Lilly And Company | Moduladores del receptor nuclear de hormonas esteroides de derivados bicíclicos sustituidos con indol |
| JP2008520674A (ja) * | 2004-11-22 | 2008-06-19 | スミスクライン ビーチャム コーポレーション | Ｈｃｖインヒビター |
| CA2588384A1 (en) | 2004-11-23 | 2006-06-22 | Ptc Therapeutics, Inc. | Tetrahydrocarbazoles as active agents for inhibiting vegf production by translational control |
| US7297704B2 (en) | 2005-02-17 | 2007-11-20 | Wyeth | Cycloalkyfused indole, benzothiophene, benzofuran and idene derivatives |
| CA2612723A1 (en) | 2005-06-24 | 2007-01-04 | Eli Lilly And Company | Tetrahydrocarbazole derivatives useful as androgen receptor modulators |
| US20090022694A1 (en) | 2005-10-18 | 2009-01-22 | Distefano Peter | Sirt1 inhibition |
| WO2008019825A1 (en) | 2006-08-14 | 2008-02-21 | Santhera Pharmaceuticals (Schweiz) Ag | Use of tricyclic indole derivatives for the treatment of muscular diseases |
| ES2396612T3 (es) | 2008-05-16 | 2013-02-22 | Eli Lilly & Company | Tetrahidrociclopenta[b]indoles como moduladores del receptor de andrógenos |
-
2007
- 2007-06-11 UA UAA200904819A patent/UA98777C2/ru unknown
- 2007-11-02 TW TW096141527A patent/TWI398438B/zh not_active IP Right Cessation
- 2007-11-05 CL CL200703182A patent/CL2007003182A1/es unknown
- 2007-11-05 AR ARP070104913A patent/AR063559A1/es active IP Right Grant
- 2007-11-06 RS RS20120056A patent/RS52191B/sr unknown
- 2007-11-06 EA EA200970500A patent/EA015627B1/ru unknown
- 2007-11-06 US US12/447,693 patent/US7968587B2/en active Active
- 2007-11-06 BR BRPI0719092A patent/BRPI0719092B8/pt active IP Right Grant
- 2007-11-06 CN CN2007800430385A patent/CN101541749B/zh active Active
- 2007-11-06 SI SI200730864T patent/SI2094658T1/sl unknown
- 2007-11-06 PT PT07844898T patent/PT2094658E/pt unknown
- 2007-11-06 NZ NZ576296A patent/NZ576296A/en not_active IP Right Cessation
- 2007-11-06 AT AT07844898T patent/ATE538091T1/de active
- 2007-11-06 ES ES07844898T patent/ES2376048T3/es active Active
- 2007-11-06 HR HR20120032T patent/HRP20120032T1/hr unknown
- 2007-11-06 MX MX2009005251A patent/MX2009005251A/es active IP Right Grant
- 2007-11-06 KR KR1020097010232A patent/KR101121471B1/ko active Active
- 2007-11-06 CA CA2670340A patent/CA2670340C/en active Active
- 2007-11-06 EP EP07844898A patent/EP2094658B1/en active Active
- 2007-11-06 WO PCT/US2007/083745 patent/WO2008063867A2/en not_active Ceased
- 2007-11-06 JP JP2009537272A patent/JP5399259B2/ja active Active
- 2007-11-06 DK DK07844898.2T patent/DK2094658T3/da active
- 2007-11-06 PL PL07844898T patent/PL2094658T3/pl unknown
- 2007-11-06 AU AU2007324046A patent/AU2007324046B2/en active Active
- 2007-11-06 MY MYPI20092021A patent/MY154547A/en unknown
- 2007-11-08 PE PE2007001544A patent/PE20081161A1/es active IP Right Grant
- 2007-11-11 JO JO2007470A patent/JO2800B1/en active
-
2009
- 2009-04-27 IL IL198410A patent/IL198410A/en active IP Right Grant
- 2009-05-05 ZA ZA200903096A patent/ZA200903096B/xx unknown
- 2009-05-15 TN TNP2009000189A patent/TN2009000189A1/fr unknown
- 2009-05-18 CO CO09050693A patent/CO6190513A2/es active IP Right Grant
- 2009-05-19 CR CR10802A patent/CR10802A/es unknown
- 2009-05-20 EC EC2009009350A patent/ECSP099350A/es unknown
- 2009-05-28 NO NO20092103A patent/NO342531B1/no unknown
- 2009-06-17 MA MA32013A patent/MA31072B1/fr unknown
-
2012
- 2012-02-14 CY CY20121100148T patent/CY1112284T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1112284T1 (el) | Ενωσεις τετραϋδροκυκλοπεντα[β] ινδολιου ως ρυθμιστες υποδοχεων ανδρογονων | |
| CY1113341T1 (el) | Ρυθμιστες υποδοχεα ανδρογονου τετραϋδροκυκλοπεντα[β]ινδολιο | |
| CY1123625T1 (el) | Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων | |
| CY1107426T1 (el) | Νεα παραγωγα φθοριογλυκοσιδιων απο πυραζολες, φαρμακευτικα προϊοντα που περιεχουν τις εν λογω ενωσεις και η χρηση αυτων | |
| CY1113159T1 (el) | Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις | |
| CY1109860T1 (el) | Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις | |
| CY1112721T1 (el) | Νεοι συνδετες που διαμορφωνουν τους υποδοχεις rαr, και χρηση αυτων στην ιατρικη για τον ανθρωπο και στα καλλυντικα | |
| CY1113963T1 (el) | Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος | |
| CY1118096T1 (el) | Ρυθμιστες υποδοχεα οπιοειδους | |
| MY148429A (en) | Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof | |
| CY1115176T1 (el) | Ρυθμιστες υποδοχεων τυπου toll | |
| MA29136B1 (fr) | Agents de potentialisation de recepteurs du glutamate | |
| ATE457979T1 (de) | Als androgen-rezeptor-modulatoren verwendbare tetrahydrocarbazol-derivate | |
| SG162804A1 (en) | Pyrazole based lxr modulators | |
| DE602006003432D1 (de) | Latoren des androgenrezeptors | |
| EA201001747A1 (ru) | Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств | |
| PA8568101A1 (es) | Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso | |
| CY1114735T1 (el) | Θεραπευτικες συνθεσεις οι οποιες περιεχουν εναν ειδικο ανταγωνιστη του υποδοχεα της ενδοθηλινης και εναν αναστολεα της pde5 | |
| CY1124301T1 (el) | Ενωσεις ινδαζολης για χρηση σε κακωσεις του τενοντα ή/και των συνδεσμων | |
| TW200640863A (en) | Compounds which potentiate glutamate receptor and uses thereof in medicine | |
| MX2009005242A (es) | Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo. | |
| IL206611A0 (en) | Novel imidazolinylmethyl aryl sulfonamides | |
| CY1115153T1 (el) | Μεθοδοι για την αγωγη δερματολογικων διαταραχων | |
| PL1732902T3 (pl) | Pochodne nukleozydów i ich terapeutyczne zastosowanie | |
| MX2010007928A (es) | Imidazolinilmetil aril sulfonamidas novedosas. |